abrdn Life Sciences Investors (HQL) To Go Ex-Dividend on November 21st

abrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Thursday, November 9th, NASDAQ reports. Investors of record on Wednesday, November 22nd will be paid a dividend of 0.30 per share on Wednesday, January 10th. This represents a $1.20 annualized dividend and a yield of 9.95%. The ex-dividend date of this dividend is Tuesday, November 21st.

abrdn Life Sciences Investors has decreased its dividend by an average of 1.0% per year over the last three years.

abrdn Life Sciences Investors Stock Up 1.3 %

HQL stock opened at $12.06 on Friday. abrdn Life Sciences Investors has a 12 month low of $11.34 and a 12 month high of $15.25. The firm’s fifty day simple moving average is $12.23 and its 200-day simple moving average is $13.05.

Insider Activity at abrdn Life Sciences Investors

In related news, President Daniel R. Omstead purchased 12,000 shares of the business’s stock in a transaction on Wednesday, September 20th. The shares were bought at an average cost of $12.68 per share, with a total value of $152,160.00. Following the transaction, the president now owns 187,422 shares of the company’s stock, valued at $2,376,510.96. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, President Daniel R. Omstead purchased 12,000 shares of the firm’s stock in a transaction on Wednesday, September 20th. The stock was bought at an average cost of $12.68 per share, with a total value of $152,160.00. Following the completion of the acquisition, the president now owns 187,422 shares of the company’s stock, valued at approximately $2,376,510.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, President Daniel R. Omstead acquired 10,096 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were purchased at an average cost of $12.39 per share, for a total transaction of $125,089.44. Following the purchase, the president now directly owns 197,518 shares in the company, valued at $2,447,248.02. The disclosure for this purchase can be found here. 10.06% of the stock is currently owned by insiders.

Institutional Investors Weigh In On abrdn Life Sciences Investors

Several hedge funds have recently modified their holdings of the company. Money Concepts Capital Corp acquired a new position in abrdn Life Sciences Investors in the 4th quarter worth about $160,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of abrdn Life Sciences Investors during the 4th quarter worth approximately $167,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of abrdn Life Sciences Investors during the 1st quarter valued at approximately $168,000. IHT Wealth Management LLC purchased a new position in shares of abrdn Life Sciences Investors during the 1st quarter valued at approximately $170,000. Finally, Eudaimonia Partners LLC acquired a new stake in abrdn Life Sciences Investors in the 1st quarter valued at $199,000. 19.70% of the stock is owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.